|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review显示文摘Despite advances in the management of patients with locally advanced,non-metastatic rectal adenocarcinoma(LARC),prognosis remains largely unsatisfactory due to a high rate of distant relapse.In fact,currently available neoadjuvant protocols,represented by fluoropyrimidine-based chemo-radiotherapy(CT-RT)or short-course RT,together with improved surgical techniques,have largely reduced the risk of local relapse,with limited impact on distant recurrence.Available results of phaseⅢtrials with additional cytotoxic agents combined with standard CT-RT are disappointing,as no significant reduction in the risk of recurrence has been demonstrated.In order to improve the control of micrometastatic disease,integrating targeted agents into neoadjuvant treatment protocols thus offers a rational approach.In particular,the antiangiogenic agent bevacizumab has demonstrated synergistic activity with both CT and RT in pre-clinical and clinical models,and thusmay represent a suitable companion in the neoadjuvant treatment of LARC.Preliminary results of phase?Ⅰ-Ⅱclinical studies are promising and suggest potential clinical parameters and molecular predictive biomarkers useful for patient selection:treatment personalization is indeed the key in order to maximize the benefit while reducing the risk of more complex neoadjuvant treatment schedules. | Lorenzo Fornaro Chiara Caparello Caterina Vivaldi Virginia Rotella Gianna Musettini Alfredo Falcone Editta Baldini Gianluca Masi | 2014 | World Journal of Gastroenterology2014，20，20： | 5 |
| 2 | FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer显示文摘Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal. FOLFIRINOX is now considered a standard treatment in first-line setting, since it demonstrated an improved overall and progression-free survival vs gemcitabine alone. However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule. After a more recent phase Ⅲ trial showing an improved outcome over gemcitabine, the combination of gemcitabine/nab-paclitaxel emerged as another standard first-line treatment. However, this treatment is also associated with more side effects. In addition, despite initial promising data on the predictive role of SPARClevels, recent studies showed that these levels are not associated with nab-paclitaxel efficacy. The choice to use this treatment over FOLFIRINOX is therefore a topic of debate, also because no validated biomarkers to guide FOLFIRINOX treatment are available. In the era of actionable mutations and target agents it would be desirable to identify molecular factors or biomarkers to predict response to therapy in order to maximize the efficacy of treatment and avoid useless toxic effects for non-responding patients. However, until today the milestone of treatment for pancreatic cancer remains chemotherapy combinations, without predictive or monitoring tools existing to optimize therapy. This review analyzes the state-of-the-art treatments, promises and limitations of targeted therapies, ongoing trials and future perspectives, including potential role of microR NAs as predictive biomarkers. | Chiara Caparello Laura L Meijer Ingrid Garajova Alfredo Falcone Tessa Y Le Large Niccola Funel Geert Kazemier Godefridus J Peters Enrico Vasile Elisa Giovannetti | 2016 | World Journal of Gastroenterology2016，22，31： | 4 |
| 3 | Anti-HER agents in gastric cancer: from bench to bedside显示文摘 | Fnrnarn L Lucehesi M Caparello C el al | 2011 | Nat Rev Gastrnenlerol Hepalol2011，8，7： | 1 |
| 4 | Liver metastases from colorectal cancer:how to best complement medical treatment with surgical approaches显示文摘 | Masi G Fornaro L Caparello C | | 0，，11： | 1 |
| 5 | Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab显示文摘 | Loupakis F Schirripa M Caparello C | | 0，，12： | 1 |
| 6 | Anti -HER agents in gastric cancer: From bench to bedside 显示文摘 | Fornaro L Lucchesi M Caparello C | 2011 | Nat Rev Gastroenterol Hepatol2011，8，7： | 1 |
| 7 | Anti-HER agents in gastric cancer: from bench to bedside 显示文摘 | Fomaro L Lucchesi M Caparello C | 2011 | Nat Rev Gastroenterol Hepatol2011，8，： | 1 |
| 8 | Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature 显示文摘 | Caparello C Vivaldi C Fornaro L | 2016 | Future Oncol2016，12，7： | 1 |
| 9 | Dissecting signaling path- ways in hepatoceilular carcinoma: new perspectives in medical ther- apy显示文摘 | Fornaro L Vivaldi C Caparello C | 2014 | Future Oncol2014，10，2： | 1 |
| 10 | Anti-HER agents in gastric cancer:from bench to bedside显示文摘 | Fornaro L Lucchesi M Caparello C | | 0，，： | 1 |
| 11 | Traditional vs wire- less intragastric pH monitoring: Are the two techniques compara- ble 显示文摘 | CAPARELLO C BRAVI I CANTEP | 2012 | Neurogastroent Motil2012，24，10： | 1 |
| 12 | Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy显示文摘 | Lorenzo Fornaro Caterina Vivaldi Chiara Caparello Rodolfo Sacco Virginia Rotella Gianna Musettini Sauro Luchi Edi Editta Baldini Alfredo Falcone Gianluca Masi | 2014 | Future Oncol2014，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员